Retrospective evaluation of pregnancies with ankylosing spondylitis in a tertiary center in Turkey.
ankylosing spondylitis
autoimmune disease
biologic agent
high risk pregnancy
rheumatic diseases
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
02
07
2019
revised:
09
10
2019
accepted:
18
10
2019
pubmed:
13
11
2019
medline:
20
11
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
To evaluate obstetrical and perinatal outcomes of pregnancies with ankylosing spondylitis (AS). This was a retrospective study evaluating obstetric outcomes of 52 patients with AS who were followed up at our institution between 2006 and 2019. Patients were classified as having disease greater than or less than 5 years, and according to disease-related medical treatment during pregnancy, as drug free, single medication or multiple medication. Overall rates of preterm delivery, intrauterine growth retardation and preeclampsia were 17.3%, 13.4% and 7.7%, respectively. Thirty-three of the patients were followed up without any medication, while 19 patients used drugs during pregnancy. Seven patients used a single drug and 12 patients had multiple drugs. There was no significant difference in terms of obstetrical and neonatal outcomes. However, a higher rate of neonatal intensive care unit (NICU) admission was observed in the group using medication for AS, despite a lack of statistical significance (31.5% vs 15%, P = .162). On the other hand, patients having disease more than 5 years had higher rates of Apgar scores less than <7 and admission to the NICU despite a lack of statistical significance (4% vs 7.4% and 16% vs 26%; P = .267 and P = .297, respectively). In conclusion, pregnancies of patients with AS must be considered as high risk due to increased rates of adverse outcomes such as preterm delivery, intrauterine growth retardation or preeclampsia.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate obstetrical and perinatal outcomes of pregnancies with ankylosing spondylitis (AS).
METHODS
METHODS
This was a retrospective study evaluating obstetric outcomes of 52 patients with AS who were followed up at our institution between 2006 and 2019. Patients were classified as having disease greater than or less than 5 years, and according to disease-related medical treatment during pregnancy, as drug free, single medication or multiple medication.
RESULTS
RESULTS
Overall rates of preterm delivery, intrauterine growth retardation and preeclampsia were 17.3%, 13.4% and 7.7%, respectively. Thirty-three of the patients were followed up without any medication, while 19 patients used drugs during pregnancy. Seven patients used a single drug and 12 patients had multiple drugs. There was no significant difference in terms of obstetrical and neonatal outcomes. However, a higher rate of neonatal intensive care unit (NICU) admission was observed in the group using medication for AS, despite a lack of statistical significance (31.5% vs 15%, P = .162). On the other hand, patients having disease more than 5 years had higher rates of Apgar scores less than <7 and admission to the NICU despite a lack of statistical significance (4% vs 7.4% and 16% vs 26%; P = .267 and P = .297, respectively).
CONCLUSION
CONCLUSIONS
In conclusion, pregnancies of patients with AS must be considered as high risk due to increased rates of adverse outcomes such as preterm delivery, intrauterine growth retardation or preeclampsia.
Identifiants
pubmed: 31713329
doi: 10.1111/1756-185X.13746
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-105Informations de copyright
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791-794.
Pompeu JE, Romano RSL, Pompeu SMAA, Lima SMAL. Static and dynamic balance in subjects with ankylosing spondylitis: literature review. Rev Bras Reumatol. 2012;52(3):413-416.
Murray H, Elliott C, Barton S, Murray A. Do patients with ankylosing spondylitis have poorer balance than normal subjects? Rheumatology (Oxford). 2000;39(5):497-500.
Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650-657.
Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol. 2008;35(2):305-309.
Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 2012;64(5):1407-1411.
Timur H, Tokmak A, Türkmen GG, Ali İnal H, Uygur D, Danışman N. Pregnancy outcome in patients with ankylosing spondylitis. J Matern Fetal Neonatal Med. 2016;29(15):2469-2473.
Lee W, Reveille JD, Weisman MH. Women with ankylosing spondylitis: a review. Arthritis Care Res (Hoboken). 2008;59(3):449-454.
Jakobsson GL, Stephansson O, Askling J, Jacobsson LT. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis. 2016;75(10):1838-1842.
Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet Gynecol. 2004;103(6):1190-1193.
Tanacan A, Unal C, Yucesoy HM, Duru SA, Beksac MS. Management and evaluation of pregnant women with Takayasu arteritis. Arch Gynecol Obstet. 2019;299(1):79-88.
Orgul G, Aktoz F, Beksac MS. Behcet’s disease and pregnancy: what to expect? J Obstet Gynaecol. 2018;38(2):185-188.
Tanacan E, Tanacan A, Fadiloglu E, Unal C, Beksac MS. Psoriasis and pregnancy: retrospective evaluation of 47 pregnancies in a tertiary center. Gynecol Obstet Reprod Med. 2018;2018:1-5.
Deodhar A, Reveille JD, Van Den Bosch F, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol. 2014;66(10):2649-2656.
Beksac K, Orgul G, Can GS, Oktem A, Kav T, Beksac MS. Management of inflammatory bowel disease and pregnancy using prophylactic low dose low molecular weight heparin and corticosteroids. J Clin Diagn Res. 2017;11(11):1-3.
Østensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis. 2004;63(10):1212-1217.
Beksaç K, Örgül G, Çağan M, Karaağaoğlu E, Arslan S, Beksaç MS. Retrospective evaluation of pregnant women with celiac disease. J Turk Ger Gynecol Assoc. 2017;18(1):56.
Giovannopoulou E, Gkasdaris G, Kapetanakis S, Kontomanolis E. Ankylosing spondylitis and pregnancy: a literature review. Curr Rheumatol Rev. 2017;13(3):162-169.
Zhou Q, Bian X-M. Liu J-t. Management of pregnancy with ankylosing spondylitis. Chin Med Sci J. 2012;27(1):46-49.
Ostensen M, Ostensen H. Ankylosing spondylitis-the female aspect. J Rheumatol. 1998;25(1):120-124.
Oestensen M, Foerger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis. 2005;64(6):839-844.
Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120(4):964-973.
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7.
Ostensen M, Ostensen H. Ankylosing spondylitis-the female aspect. J Rheumatol. 1998;25(1):120-124.
Zhou Q, Bian XM, Liu JT. Management of pregnancy with ankylosing spondylitis. Chin Med Sci J. 2012;27(1):46-49.
Roux C, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology. 2006;46(4):695-698.
Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFa monoclonal antibody. Hum Exp Toxicol. 2000;19(4):226-228.
Bermas BL.Safety of rheumatic disease medication use during pregnancy and lactation. (2019). Retrieved from https://www.uptodate.com/contents/safety-of-rheumatic-diseasemedication-use-during-pregnancy-and-lactation/print
Østensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013;13(3):470-475.